Market Size of Hepatitis Therapeutics Industry
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 3.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Hepatitis Therapeutics Market Analysis
During the time frame of the forecast, the hepatitis therapeutics market is expected to grow at a CAGR of 3.5%.
The impact of COVID-19 on healthcare services had a substantial impact on the delivery of care and outcomes for patients with chronic diseases. Therefore, there was a decline in the treatment, diagnosis, and follow-up of patients with hepatitis B and C, which had a significant impact on the healthcare industry. Additionally, clinical trials of the drugs were reduced as more and more companies delayed the start of most new courses in several countries. In addition, the COVID-19 epidemic saw a decline in outpatient services for patients with chronic hepatitis, which also had a significant impact on overall market growth. The study published in July 2021 in PubMed stated that the COVID-19 pandemic affected hepatitis prevention, testing, treatment, and vaccination services globally. But the return of elective care procedures around the world is likely to bring the market's growth back to where it was before the pandemic.
The market is anticipated to witness rapid growth due to the growing incidence of hepatitis, growing government support for awareness of hepatitis diseases, and increased availability of highly technologically advanced medical products. Hepatitis is an inflammation of the liver. Hepatitis may be due to drugs, alcohol consumption, or other medical conditions affecting the liver. But in most cases, it is caused by a virus called viral hepatitis, and the most common types are hepatitis A, B, and C. Hepatitis B is very common and can lead to severe cirrhosis of the liver, which can be fatal. Moreover, government initiatives to increase awareness regarding hepatitis and its treatment are anticipated to boost market growth over the forecast period. For instance, in June 2022, the "World Hepatitis Summit (WHS)" occurred as a virtual event. The World Hepatitis Summit 2022 was co-sponsored by the World Health Organization (WHO). The summit provides a platform for a broad hepatitis community to take stock of progress to date and share ideas, experiences, and best practises in addressing the many challenges of viral hepatitis.
Furthermore, according to the Hepatitis B Foundation 2022 update, two billion people have been infected with the hepatitis B virus (one out of three people). Approximately 1.5 million people become newly infected each year. Almost 300 million people are chronically infected. Thus, the increasing burden of hepatitis is propelling the growth of the market. Additionally, in March 2021, Dicerna Pharmaceuticals and Roche commenced the Phase II combination trial of the investigational GalXC RNAi candidate, RG6346, for the treatment of chronic hepatitis B virus (HBV) infection. In addition, in March 2022, VBI Vaccines Inc. received FDA approval for the 3-antigen HBV vaccine for adults in the United States, PreHevbrio for hepatitis B. Therefore, such research and development activities in the market are expected to drive market growth.
Therefore, the increase in the prevalence of the hepatitis B virus, the promising pipeline for hepatitis drugs, and government-sponsored programmes to encourage patients to accept hepatitis drugs are likely to drive the hepatitis therapeutics market over the forecast period. During the analysis period, the market is likely to grow slowly because of strict regulations and bad reimbursement policies.
Hepatitis Therapeutics Industry Segmentation
As per the scope of the report, hepatitis is an inflammation of the liver. The standard treatment for treating hepatitis includes several antiviral medications for different types of hepatitis, namely A, B, and C. The most effective therapy for combating the condition is a combination of different drugs. The Hepatitis Therapeutics Market is classified into Disease Type (Hepatitis A, B, C, D, and Others), Drug Class (Interferon, Monoclonal Antibody, Non-structural Protein 5A (NS5A) Inhibitors, Nucleotide Analog Reverse Transcriptase Inhibitors, Nucleotide Analog NS5B Polymerase Inhibitors, Multi-Class Combination, and Others), and Geography (North America, Europe, The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Disease Type | |
| Hepatitis A | |
| Hepatitis B | |
| Hepatitis C | |
| Hepatitis D | |
| Other Types |
| By Drug Class | |
| Interferon | |
| Monoclonal Antibody | |
| Non-structural protein 5A (NS5A) Inhibitors | |
| Nucleotide Analog Reverse Transcriptase Inhibitors | |
| Nucleotide Analog NS5B Polymerase Inhibitors | |
| Multi Class Combination | |
| Other Drug Classes |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Hepatitis Therapeutics Market Size Summary
The hepatitis therapeutics market is poised for growth, driven by an increasing incidence of hepatitis infections and supportive government initiatives aimed at raising awareness and improving treatment options. The market experienced a temporary setback due to the COVID-19 pandemic, which disrupted healthcare services and delayed clinical trials, impacting the diagnosis and treatment of hepatitis B and C. However, the resumption of elective care procedures and the introduction of advanced medical products are expected to restore and enhance market growth. Hepatitis, primarily caused by viral infections, remains a significant health concern, with hepatitis B and C being the most prevalent types. Government-sponsored programs and global health summits, such as the World Hepatitis Summit, are playing a crucial role in addressing the challenges posed by viral hepatitis, thereby fostering market expansion.
The market is characterized by the presence of major players and a competitive landscape, with companies like Merck & Co., Inc., Gilead Sciences, Inc., and AbbVie Inc. leading the charge. The North American region is anticipated to hold a significant market share due to the high prevalence of hepatitis, favorable reimbursement policies, and a robust healthcare infrastructure. The introduction of new products and strategic government plans, such as the Viral Hepatitis National Strategic Plan in the United States, are further propelling market growth. Despite challenges such as strict regulations and reimbursement issues, the market is expected to benefit from ongoing research and development activities, including clinical trials and product approvals, which are crucial for advancing hepatitis treatment options.
Hepatitis Therapeutics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Viral Hepatitis
-
1.2.2 Favorable Government Support for Creating Awareness about Hepatitis
-
1.2.3 Increasing Availability of Technologically Advanced Therapeutic Products
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulatory Issues
-
1.3.2 Poor Reimbursement Policies
-
-
1.4 Industry Attractiveness - Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Buyers/Consumers
-
1.4.2 Bargaining Power of Suppliers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
2.1 By Disease Type
-
2.1.1 Hepatitis A
-
2.1.2 Hepatitis B
-
2.1.3 Hepatitis C
-
2.1.4 Hepatitis D
-
2.1.5 Other Types
-
-
2.2 By Drug Class
-
2.2.1 Interferon
-
2.2.2 Monoclonal Antibody
-
2.2.3 Non-structural protein 5A (NS5A) Inhibitors
-
2.2.4 Nucleotide Analog Reverse Transcriptase Inhibitors
-
2.2.5 Nucleotide Analog NS5B Polymerase Inhibitors
-
2.2.6 Multi Class Combination
-
2.2.7 Other Drug Classes
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Hepatitis Therapeutics Market Size FAQs
What is the current Hepatitis Therapeutics Market size?
The Hepatitis Therapeutics Market is projected to register a CAGR of 3.5% during the forecast period (2024-2029)
Who are the key players in Hepatitis Therapeutics Market?
AbbVie Inc., Bristol Myers Squibb Company, F Hoffmann-La Roche Ltd, Gilead Sciences Inc. and Merck KGaA are the major companies operating in the Hepatitis Therapeutics Market.
